C4X Discovery Holdings PLC C4X Discovery Holdings plc: Board Change (2222D)
June 20 2023 - 1:00AM
UK Regulatory
TIDMC4XD
RNS Number : 2222D
C4X Discovery Holdings PLC
20 June 2023
C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Board Change
20 June 2023 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering Drug Discovery company, today announces that Eva-Lotta
Allan will step down as Chair after five years of service with
immediate effect. Clive Dix will simultaneously become interim
Executive Chair and a search will commence to find a new Chief
Executive Officer. Clive Dix, who has held a variety of leadership
roles at C4XD over the past nine years, will be interim Executive
Chair until a new CEO is appointed in order to ensure a smooth
transition, after which point it is expected that he will assume a
Non-Executive Board role.
Eva-Lotta became Chair in July 2018 and steps down now to focus
on her portfolio of other Board director roles. The search will now
be initiated to recruit a new CEO of C4XD, ideally with strong
leadership skills, an international network and IR experience in
global public markets, and a track record of building a company
with products that have entered clinical development.
Clive Dix, CEO of C4XD, said: "I would like to thank Eva-Lotta,
both personally and on behalf of the Board for her guidance and
support over the past five years as, together, we have built C4XD
into a strong company with an established reputation for drug
discovery expertise. The business is one I feel extremely confident
and passionate about and I look forward to working with the Board
to find a suitable CEO successor to continue to drive our new
strategy forward with the focus in immuno-inflammatory
diseases."
Eva-Lotta Allan, Chair of C4XD, commented: "Over the past five
years we have built a commercially attractive pipeline and executed
several value-creating deals for C4XD programmes with leading
pharma companies and, after five years, I now feel it is the right
time to hand the reigns to Clive as interim Executive Chair. A
smooth succession plan will allow us to bring in a new CEO with the
right experience to take the Company to its next stage , thereby
ensuring that C4XD continues to deliver on its vision, strategy
and, most importantly new therapies to improve the lives of
patients with immuno-inflammatory diseases. I have enjoyed working
with the CX4D team and the Board and wish everyone at C4XD
well."
- Ends -
Contacts
C4X Discovery Holdings
Mo Noonan, Communications +44 (0)787 6444977
Panmure Gordon (UK) Limited (NOMAD and
Broker)
Freddy Crossley, Emma Earl (Corporate
Finance) +44 (0)20 7886 2500
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic
Communications
Mary-Jane Elliott, Chris Gardner, Matthew
Neal +44 (0)203 709 5700
Notes to Editors:
About C4X Discovery
C4X Discovery ("C4XD") is a pioneering Drug Discovery company,
combining scientific expertise with cutting-edge Drug Discovery
technologies to efficiently deliver world--leading medicines. We
have a highly valuable and differentiated approach to Drug
Discovery through our enhanced candidate molecule design and
patient stratification capabilities, generating small molecule drug
candidates across multiple disease areas focused on
immuno-inflammation. Our commercially attractive portfolio ranges
from early-stage target opportunities to late-stage Drug Discovery
programmes and we have three commercially partnered programmes with
one candidate in clinical development.
For more information visit us at www.c4xdiscovery.com or follow
us on twitter @C4XDiscovery.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCSFDFUUEDSEEM
(END) Dow Jones Newswires
June 20, 2023 02:00 ET (06:00 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024